Treatment of neuromyelitis optica: Review and recommendations

Bakker, 2004, Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG), The Canadian Journal of Neurological Sciences, 31, 265, 10.1017/S0317167100053932 Barnett, 2012, Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy, Multiple Sclerosis, 18, 108, 10.1177/1352458511421185 Bedi, 2011, Impact of rituximab on relapse rate and disability in neuromyelitis optica, Multiple Sclerosis, 17, 1225, 10.1177/1352458511404586 Bennett, 2009, Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica, Annals of Neurology, 66, 617, 10.1002/ana.21802 Bichuetti, 2010, Neuromyelitis optica treatment: analysis of 36 patients, Archives of Neurology, 67, 1131, 10.1001/archneurol.2010.203 Bonnan, 2009, Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder, Multiple Sclerosis, 15, 487, 10.1177/1352458508100837 Bradl, 2009, Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo, Annals of Neurology, 66, 630, 10.1002/ana.21837 Carson, 2009, Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project, The Lancet Oncology, 10, 816, 10.1016/S1470-2045(09)70161-5 Costanzi, 2011, Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica, Neurology, 77, 659, 10.1212/WNL.0b013e31822a2780 Cree, 2005, An open label study of the effects of rituximab in neuromyelitis optica, Neurology, 64, 1270, 10.1212/01.WNL.0000159399.81861.D5 DRUGDEX® System [Internet database]. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Emery, 2006, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis and Rheumatism, 54, 1390, 10.1002/art.21778 Falcini, 2006, Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment, Rheumatology (Oxford), 45, 913, 10.1093/rheumatology/kei263 Genentech: Products - Product Information - Immunology - Rituxan RA Full Prescribing Information. Gisbert, 2008, Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review, The American Journal of Gastroenterology, 103, 1783, 10.1111/j.1572-0241.2008.01848.x Greenberg, 2007, Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide, Neurology, 68, 1614, 10.1212/01.wnl.0000260970.63493.c8 Hauser, 2008, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, The New England Journal of Medicine, 358, 676, 10.1056/NEJMoa0706383 Herges, 2012, Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein, Multiple Sclerosis, 18, 398, 10.1177/1352458512440060 Hinson, 2007, Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica, Neurology, 69, 2221, 10.1212/01.WNL.0000289761.64862.ce Jacob, 2009, Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients, Archives of Neurology, 66, 1128, 10.1001/archneurol.2009.175 Jacob, 2008, Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients, Archives of Neurology, 65, 1443, 10.1001/archneur.65.11.noc80069 Jarius, 2008, Antibody to aquaporin-4 in the long-term course of neuromyelitis optica, Brain, 131, 3072, 10.1093/brain/awn240 Kandiel, 2005, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, 54, 1121, 10.1136/gut.2004.049460 Kim, 2011, Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years, Archives of Neurology, 68, 1412, 10.1001/archneurol.2011.154 Kim, 2011, Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica, Archives of Neurology, 68, 473, 10.1001/archneurol.2010.322 Kinoshita, 2010, Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells, Biochemical and Biophysical Research Communications, 394, 205, 10.1016/j.bbrc.2010.02.157 Kleiter, 2012, Failure of natalizumab to prevent relapses in neuromyelitis optica, Archives of Neurology, 69, 239, 10.1001/archneurol.2011.216 Lennon, 2005, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel, The Journal of Experimental Medicine, 202, 473, 10.1084/jem.20050304 Lucchinetti, 2002, A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica, Brain, 125, 1450, 10.1093/brain/awf151 Luhder, 2009, Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy, Critical Reviews in Immunology, 29, 255, 10.1615/CritRevImmunol.v29.i3.50 Mandler, 1998, Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine, Neurology, 51, 1219, 10.1212/WNL.51.4.1219 McKeon, 2008, CNS aquaporin-4 autoimmunity in children, Neurology, 71, 93, 10.1212/01.wnl.0000314832.24682.c6 Min, 2012, Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder, Multiple Sclerosis, 18, 113, 10.1177/1352458511431973 Minagar, 2000, Treatment of Devic's disease with methotrexate and prednisone, International Journal of MS Care, 2, 39, 10.7224/1537-2073-2.4.43 Molloy, 2011, PML and rheumatology: the contribution of disease and drugs, Cleveland Clinic Journal of Medicine, 78, S28, 10.3949/ccjm.78.s2.07 Nakashima, 2011, Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels, Journal of Clinical Neuroscience, 18, 997, 10.1016/j.jocn.2010.12.011 Neff, 2008, Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation, Transplantation, 86, 1474, 10.1097/TP.0b013e31818b62c8 Okada, 2007, Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica, Internal Medicine, 46, 1671, 10.2169/internalmedicine.46.0217 Palace, 2010, Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers, Archives of Neurology, 67, 1016, 10.1001/archneurol.2010.188 Papeix, 2007, Immunosuppressive therapy is more effective than interferon in neuromyelitis optica, Multiple Sclerosis, 13, 256, 10.1177/1352458506070732 Pellkofer, 2011, Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab, Neurology, 76, 1310, 10.1212/WNL.0b013e3182152881 Priest, 2006, Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease, Pharmacoeconomics, 24, 767, 10.2165/00019053-200624080-00004 Saadoun, S, Waters, P. et al. (2011). Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (e-pub). Sahraian, 2010, Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients, European Journal of Neurology, 17, 794, 10.1111/j.1468-1331.2009.02928.x Sato, 2012, Treatment of neuromyelitis optica: an evidence based review, Arquivos de Neuro-Psiquiatria, 70, 59, 10.1590/S0004-282X2012000100012 Shimizu, 2010, IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum, Neurology, 75, 1423, 10.1212/WNL.0b013e3181f8832e Tradtrantip, 2012, Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica, Annals of Neurology, 71, 314, 10.1002/ana.22657 Uzawa, 2010, Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis, European Journal of Neurology, 17, 672, 10.1111/j.1468-1331.2009.02897.x Van Herle, 2012, Integrative continuum: accelerating therapeutic advances in rate autoimmune diseases, Annual Review of Pharmacology and Toxicology, 52, 523, 10.1146/annurev-pharmtox-010611-134628 Vose, 2001, Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, Journal of Clinical Oncology, 19, 389, 10.1200/JCO.2001.19.2.389 Watanabe, 2007, Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis, Multiple Sclerosis, 13, 968, 10.1177/1352458507077189 Watanabe, 2007, Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica, Multiple Sclerosis, 13, 128, 10.1177/1352458506071174 Weinshenker, 1999, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, Annals of Neurology, 46, 878, 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q Weinshilboum, 1980, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, American Journal of Human Genetics, 32, 651 Weinstock-Guttman, 2006, Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease), Archives of Neurology, 63, 957, 10.1001/archneur.63.7.957 Wingerchuk, 2006, Revised diagnostic criteria for neuromyelitis optica, Neurology, 66, 1485, 10.1212/01.wnl.0000216139.44259.74 Wingerchuk, 2007, A secondary progressive clinical course is uncommon in neuromyelitis optica, Neurology, 68, 603, 10.1212/01.wnl.0000254502.87233.9a Wingerchuk, 2008, Neuromyelitis optica, Curr Treat Options Neurol, 10, 55, 10.1007/s11940-008-0007-z Wingerchuk, 2011, White matter disease: optimizing rituximab therapy for neuromyelitis optica, Nature Reviews Neurology, 7, 664, 10.1038/nrneurol.2011.154